Zevra Therapeutics, Inc. ZVRA Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 86.1%+7.2pp | 84.5%+15.9pp | 80.7%+13.5pp | 72%-3.2pp | 78.8%-10.3pp | |
| Net margin | 101.6%+328pp | 78.2%+525pp | 41.9%+408pp | 4.3%— | -226.6%— | |
| Returns | ||||||
| Return on equity | 100.7%+305pp | 85.7%+294pp | 34.8%+171pp | 3.5%— | -204.8%— | |
| Return on invested capital | -0.1%— | -49.9%— | -53.2%— | -64.6%— | —— | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.3× | 0.5×+0.3× | 0.4×+0.2× | 0.3×+0.1× | 0.3×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.9×+1.9× | 5.7×+3.2× | 8.6×+5.7× | 7.9×+5.9× | 3×+0.9× | |
| Leverage | ||||||
| Debt-to-equity | 0×-1.5× | 0.4×-1.1× | 0.5×-0.4× | 0.5×-1.3× | 1.5×+1.4× | |
| Per Share | ||||||
| Book value per share | $3.42+351% | $2.70— | $2.38— | $2.08— | $0.76— | |
| Valuation | ||||||
| Market capitalization | $773.23M+56.4% | $504.43M+13.3% | $533.84M+83.6% | $500.32M+144% | $405.33M+84.4% | |
| Price / earnings | 6.2×— | —— | —— | —— | —— | |
| Price / sales | 6.3×-5.9× | 4.7×-14.1× | 6.3×-5.5× | 8.1×-0.6× | 10×+2.1× | |
| Price / book | 3.8×-8.3× | 3.3×-8.0× | 4×-0.2× | 4.3×-2.0× | 9.9×+5.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Zevra Therapeutics, Inc.'s profit margins?
- Zevra Therapeutics, Inc. (ZVRA) runs a 86.1% gross margin and a -103.9% operating margin, with a 101.6% net margin.
- Where do Zevra Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Zevra Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
